IB IBRX ImmunityBio, Inc. Common Stock Loading... : Bullish and Bearish Analyst Opinions

Author includes IBRX as a high-risk, high-reward long-term pick, no catalyst stated.

The author lists seven thematic long-term bets across tech and biotech but frames them as a research write-up rather than current personal positions, so each is indexed as watch.

Named as one of author's preferred health/bio sector picks in a multi-theme favorite-stocks list backed by personal research.

Author lists favorite stocks per sector and explicitly states IREN, HIMS, and ONDS are top picks for 2026, with ownership of most names, indicating a long bias across the basket.

Author lists favorite stocks per sector with IREN, HIMS, and ONDS as top 2026 picks, but only IREN and HIMS are explicitly owned as current long positions while the rest are watchlist mentions.

Author names IBRX as a personal long-term favorite in Biotech/Immunotherapy; no specific catalyst or reasoning provided.

The author lists their favorite long-term stocks with a write-up planned, indicating a bullish conviction on each ticker as a core holding.

Author lists six stocks as favorite long-term holdings with planned write-ups, indicating a confident bullish conviction on each.

Author announces a Substack relaunch with free research blueprints on these stocks but does not state any current positions or forward-looking trade calls.

Speculative biotech with commercial progress.

Author is actively seeking an entry point in IBRX, indicating bullish interest but no confirmed position yet.

The author explicitly calls these seven stocks the easiest long-term holds, indicating a confident bullish position on each ticker.

Author added TEM and INFQ to their portfolio as long-term holdings and is now watching IBRX and SMR for potential entries.

Buy IBRX as an FDA-approved, revenue-generating biotech with ANKTIVA already commercialized in bladder cancer; pipeline expansion into lung, GBM, and pancreatic cancer plus Saudi Arabia's NSCLC approval provide multiple re-rating catalysts beyond current bladder-cancer-only valuation.

Buy IBRX as a differentiated biotech with an already-approved, revenue-generating product (ANKTIVA) and a multi-indication platform thesis spanning bladder, lung, and brain cancer, plus international expansion into Saudi Arabia — reducing binary risk typical of pre-revenue peers.

The author identifies these six stocks as long-term convictions to buy on red days, implying a bullish position in each.

The author lists favorite stocks by sector as a thematic watchlist without explicitly stating current positions or forward calls, so each ticker is indexed as watch.

The author lists favorite stocks per sector as a thematic watchlist without explicitly stating current positions or forward calls, so all tickers are indexed as watch.

The author outlines a hypothetical long-term portfolio of nine names built for asymmetric upside, implying a bullish conviction on each ticker as core holdings.

Long IBRX as a speculative biotech pick in the author's retirement list.

Anktiva approved across 33 countries; portfolio position.

Bought IBRX not too long ago and plans to add to position.

The tweet expresses sympathy regarding a tragic event while mentioning tickers without providing a financial outlook.

Despite an FDA warning letter causing a sharp price drop, the author views the decline as a buying opportunity for long-term investors.

Neuner mentions he told people to invest in ImmunityBio (IBRX) because they "may have just found a cure for cancer." He uses this to illustrate the necessity of a strong "Why" for investing. Unlike Bitcoin's currently muddied narrative, a biotech breakthrough offers a clear, compelling reason for capital allocation. LONG based on the "strong narrative" thesis. Clinical trial failures or regulatory rejections (standard biotech binary risk).

The stock is undervalued because its price has not yet reflected the company's positive clinical progress.

The speaker states a "Gamma squeeze incoming" for IBRX. A gamma squeeze is a rapid price increase driven by market makers hedging their short gamma exposure from sold call options. As the stock price rises, they must buy more shares, pushing the price even higher in a feedback loop. The user is extremely bullish on IBRX in the very short term, anticipating a rapid, options-driven price surge. Gamma squeezes are speculative, difficult to time, and can fail to materialize. If the expected buying pressure doesn't occur, the stock could fall, and any options purchased would lose value rapidly.